Clinical trials: Thoracic Neoplasm
Lung Cancer, Pneumothorax
Outpatient Chest Tube Management Following Thoracic Resection Improves Patient Length of Stay and Satisfaction Without Compromising Outcomes
Discharging patients home with air leak and chest tube to portable drainage device after thoracic resection is cost effective and safe without compromising patients outcome or satisfaction.
- Conditions
- Lung Cancer, Pneumothorax, Subcutaneous Emphysema
- Trial name
- NCT01551082
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Alliance of Cardiothoracic and Vascular Surgeons
Non-Small Cell Lung Cancer
Ridaforolimus With Cetuximab: Adv Non-Small Cell Lung, Colorectal, Head & Neck Cancer
The main purpose of this study is to evaluate the best dose, safety and side effects of ridaforolimus when given with cetuximab for patients with head and neck, lung and colon cancer that has progressed after initial therapy.
- Trial name
- NCT01212627
- Testing
- Ridaforolimus
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Angela Taber MD
Dysphagia, Non-Small Cell Lung Cancer
Study to Evaluate Palifermin in the Reduction of Dysphagia in Patients With Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to determine if palifermin will reduce the incidence of dysphagia in patients receiving concurrent chemoradiotherapy followed by consolidation chemotherapy for treatment of unresectable stage III…
- Conditions
- Dysphagia, Non-Small Cell Lung Cancer, Lung Cancer
- Trial name
- NCT00094861
- Testing
- Palifermin, Radiotherapy, Paclitaxel
- Volunteers
- 100 people
- Sponsor
- Swedish Orphan Biovitrum
Small Cell Lung Carcinoma
Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)
This study will evaluate the combination of a fixed dose pembrolizumab/vibostolimab co-formulation (MK-7684A) with etoposide/platinum chemotherapy followed by MK-7684A compared to the combination of atezolizumab with…
- Trial name
- NCT05224141
- Testing
- Pembrolizumab/Vibostolimab Co-Formulation, Etoposide, Cisplatin
- Where
- 140 sites in United States, Argentina and 23 more
- Volunteers
- 460 people
- Sponsor
- Merck Sharp & Dohme LLC
Breast Cancer, Colon Cancer
Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer
This pilot clinical trial studies copper Cu 64 anti-carcinoembryonic antigen (CEA) monoclonal antibody M5A positron emission tomography (PET) in diagnosing patients with CEA positive cancer.
- Conditions
- Breast Cancer, Colon Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer
- Trial name
- NCT02293954
- Testing
- radionuclide imaging, positron emission tomography, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- City of Hope Medical Center
Non-Small Cell Lung Cancer
Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)
This Phase III study will be conducted to evaluate the efficacy and safety of YH25448 as first-line treatment in locally advanced or metastatic Non-small Cell Lung Cancer (NSCLC) patients with EGFR mutations
- Trial name
- NCT04248829
- Testing
- Lazertinib 240 mg/160 mg, Gefitinib 250 mg
- Where
- 80 sites in Australia, Greece and 11 more
- Volunteers
- 393 people
- Sponsor
- Yuhan Corporation
Lung Cancer
Pemetrexed &Oxaliplatin in Patients w Recurrent NSCLCa After Failure to Platinum Based Adjuvant Chem
The purpose of this study is: To find out if the chemotherapy treatment using Pemetrexed (Alimta) and Oxaliplatin (Eloxatin) given together will kill the cancer cells in the patient's body and shrink the size of their tumor.
- Trial name
- NCT00612677
- Testing
- Oxaliplatin, Pemetrexed
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Carcinoma, Non-Small-Cell Lung
Study Of CP-751,871 In Combination With Cisplatin And Gemcitabine In Chemotherapy-Naïve Patients With Advanced Non-Small Cell Lung Cancer
CP 751,871 is a fully human monoclonal antibody against the Insulin-Like Growth Factor 1 Receptor (IGF-1R). Preclinical and clinical data indicate that CP 751,871 augments the anti-tumor activity of chemotherapy.
- Trial name
- NCT00560573
- Testing
- CP-751,871, Cisplatin, Gemcitabine
- Where
- 4 sites in Belgium, Ireland and 1 more
- Volunteers
- 46 people
- Sponsor
- Pfizer
Carcinoma, Non Small Cell Lung
Trial Of PF-00299804 In Patients With Advanced Refractory Lung Cancer
To assess the safety and efficacy of PF-00299804 in patients with advanced lung cancer.
- Trial name
- NCT00553254
- Testing
- PF-00299804
- Where
- 3 sites in South Korea
- Volunteers
- 55 people
- Sponsor
- Pfizer
Lung Cancer
Irinotecan, Carboplatin and Radiation Therapy Followed by Bevacizumab in Limited Stage Small Cell Lung Cancer
In this multicenter trial, we plan to evaluate the feasibility and toxicity of initial treatment with irinotecan/carboplatin/radiation therapy, followed by treatment with bevacizumab, in patients with limited stage small cell…
- Trial name
- NCT00193375
- Testing
- Irinotecan, Carboplatin, Bevacizumab
- Volunteers
- 60 people
- Sponsor
- SCRI Development Innovations, LLC
Neoplasms, Neoplasm Metastasis
A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread
The main objective of the dose-escalation parts of the trial is to determine the maximum tolerated dose (MTD), based on the frequency of patients experiencing dose-limiting toxicities (DLTs), and/or the recommended dose for…
- Conditions
- Neoplasms, Neoplasm Metastasis, Carcinoma, Non-Small-Cell Lung
- Trial name
- NCT03166631
- Testing
- BI 891065, BI 754091
- Where
- 3 sites in United States
- Volunteers
- 62 people
- Sponsor
- Boehringer Ingelheim
Non Small Cell Lung Cancer
A Study of HBI-8000 (Tucidinostat) With Pembrolizumab in Non-Small Cell Lung Cancer
A Phase 2 Study to Assess the Safety and Efficacy of HBI-8000 in Combination with Pembrolizumab for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
- Trial name
- HBI-8000 (NCT05141357)
- Testing
- HBI-8000 in combination with pembrolizumab
- Where
- 7 sites in United States
- Volunteers
- 5 people
- Sponsor
- HUYABIO International, LLC.
Malignant Pleural Mesothelioma, Mesothelioma
Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma
The purpose of this study is to determine whether the transarterial chemoperfusion treatment with cisplatin, methotrexate and gemcitabine is safe and effective in adults with malignant pleural mesothelioma (MPM).
- Trial name
- NCT02611037
- Testing
- Cisplatin, Methotrexate, Gemcitabine
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Small Cell Lung Carcinoma
Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer
The purpose of this multicenter study in China is to evaluate the safety and efficacy of tiragolumab plus atezolizumab and carboplatin and etoposide (CE) compared with placebo plus atezolizumab and CE in participants with…
- Trial name
- SKYSCRAPER-02C (NCT04665856)
- Testing
- Tiragolumab, Atezolizumab, Carboplatin
- Where
- 16 sites in China
- Volunteers
- 123 people
- Sponsor
- Hoffmann-La Roche
Non-Small Cell Lung Cancer (NSCLC)
Vorinostat in Combination With Palliative Radiotherapy for Patients With Non-Small Cell Lung Cancer
This is a dose escalation study that will assess the safety of Vorinostat, a Histone Deacetylase (HDAC) inhibitor, in combination with palliative radiotherapy in patients with advanced or metastatic Non-Small Cell Lung Cancer…
- Trial name
- NCT00821951
- Testing
- Vorinostat, Radiotherapy
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Yale University
Recurrent Small Cell Lung Cancer
Rovalpituzumab Tesirine (SC16LD6.5) in Recurrent Small Cell Lung Cancer
The purpose of this study is to assess the safety and tolerability of rovalpituzumab tesirine (SC16LD6.5) at different dose levels in patients with small cell lung cancer whose cancer has progressed or recurred following standard…
- Trial name
- NCT01901653
- Testing
- Rovalpituzumab tesirine (SC16LD6.5)
- Where
- 8 sites in United States
- Volunteers
- 82 people
- Sponsor
- Stemcentrx
Non-small Cell Lung Cancer (NSCLC)
Calypso-based Deep Inspiration Breath Hold (DIBH) Radiation Treatments of Lung Cancer
The purpose of this study is to test the use of Calypso beacon implants as a way to determine where the lung tumor is located during radiation treatment.
- Trial name
- NCT02111681
- Testing
- Calypso Beacon Implantation
- Where
- 4 sites in United States
- Volunteers
- 48 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Lung Cancer
Real World Utilization and Outcomes With Dacomitinib First Line Treatment for EGFR Mutation-positive Advanced Non Small Cell Lung Cancer Among Asian Patients - A Multi Center Chart Review
This is a longitudinal, consecutive case-series, multi-center study with mixed prospective and retrospective data collection. Data will be collected from eligible adults with EGFR mutation-positive advanced non-small cell lung…
- Trial name
- NCT04609319
- Testing
- Dacomitinib
- Where
- 14 sites in China, India and 1 more
- Volunteers
- 307 people
- Sponsor
- Pfizer
Lung Cancer
Evaluation of Computer-Aided Lung Nodule Detection Software in Thoracic CT for Riverain Technologies LLC
STUDY DESIGN: This is a retrospective, multi-reader, multi-case, (MRMC) randomized reader study. OBJECTIVE: Primary: The primary objective of this clinical study is to prove that a user aided with ClearRead CT InSight (CRCTI) is…
- Trial name
- NCT02440139
- Testing
- ClearRead CT Insight
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Virginia Polytechnic Institute and State University
Non-small Cell Lung Cancer
A Study Comparing the Efficacy and Safety Between IBI308 and Docetaxel in Patients With Advanced or Metastatic NSCLC
Clinical trial results demonstrate that anti-PD-1 antibodies prolonged OS to approximately 9 months compared with 6 months in docetaxel group.
- Trial name
- NCT03150875
- Testing
- IBI308, Docetaxel
- Where
- 2 sites in China
- Volunteers
- 290 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.